Biomedical HIV prevention is advancing rapidly and offers new opportunities to reshape the global HIV epidemic. This dynamic and timely SYNC 2025 plenary session will delve into the latest development in HIV prevention: the twice-yearly injectable lenacapavir (LEN) as PrEP, which is a transformative tool for reducing HIV transmission, particularly among those who face challenges with daily adherence, stigma, or access to health care.